SUMMARY

• Perseris^® (risperidone) and Uzedy^® (risperidone) are not Janssen products.^1,2
• Perseris^® and Uzedy^® are subcutaneous, long-acting injectables available as once monthly and once monthly or once every 2 months, respectively.^1,2
• There are currently no head-to-head studies examining the efficacy and safety of RISPERDAL CONSTA compared to the once monthly or once every 2 months subcutaneous risperidone injections.³
• The subcutaneous risperidone injections are not substitutable generics for any product currently on the market.

BACKGROUND

Perseris (90 mg or 120 mg) is administered once monthly as a subcutaneous injection in the abdomen or back of the upper arm by a healthcare professional and is indicated for the treatment of schizophrenia in adults.¹

Uzedy (50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, and 250 mg) is administered either once monthly or once every 2 months in the abdomen or upper arm via subcutaneous injection by a healthcare professional. Uzedy is indicated for the treatment of schizophrenia in adults.²

For questions on these products, please refer to their respective manufacturer.^1,2

RISPERDAL CONSTA (12.5 mg, 25 mg, 37.5 mg, and 50 mg) is administered every 2 weeks by deep intramuscular deltoid or gluteal injection by a healthcare professional. RISPERDAL CONSTA is indicated in adults for the treatment of schizophrenia, and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder. Oral risperidone (or another antipsychotic medication) should be given with the first injection of RISPERDAL CONSTA and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from RISPERDAL CONSTA.³

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 09 April 2024.